The first author (S.M.G.) is a Fellow in the Department of Urology, University of Michigan, and is supported, in part, by an NIH T32 training grant (NIH 2 T32 DK007782-06).
Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI)
Article first published online: 15 MAR 2007
Copyright © 2007 American Cancer Society
Volume 109, Issue 9, pages 1756–1762, 1 May 2007
How to Cite
Gilbert, S. M., Wood, D. P., Dunn, R. L., Weizer, A. Z., Lee, C. T., Montie, J. E. and Wei, J. T. (2007), Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer, 109: 1756–1762. doi: 10.1002/cncr.22556
- Issue published online: 18 APR 2007
- Article first published online: 15 MAR 2007
- Manuscript Accepted: 2 JAN 2007
- Manuscript Revised: 23 DEC 2006
- Manuscript Received: 12 OCT 2006
- bladder cancer;
- health-related quality of life assessment;
- cancer outcomes
Health-related quality of life (HRQOL) has not been adequately measured in bladder cancer. A recently developed reliable and disease-specific quality of life instrument (Bladder Cancer Index, BCI) was used to measure urinary, sexual, and bowel function and bother domains in patients with bladder cancer managed with several different interventions, including cystectomy and endoscopic-based procedures.
Patients with bladder cancer were identified from a prospective bladder cancer outcomes database and contacted as part of an Institutional Review Board-approved study to assess treatment impact on HRQOL. HRQOL was measured using the BCI across stratified treatment groups. Bivariate and multivariable analyses adjusted for age, gender, income, education, relationship status, and follow-up time were performed to compare urinary, bowel, and sexual domains between treatment groups.
In all, 315 bladder cancer patients treated at the University of Michigan completed the BCI in 2004. Significant differences were seen in mean BCI function and bother scores between cystectomy and native bladder treatment groups. In addition, urinary function scores were significantly lower among cystectomy patients treated with continent neobladder compared with those treated with ileal conduit (all pairwise P < .05).
The BCI is responsive to functional and bother differences in patients with bladder cancer treated with different surgical approaches. Significant differences between therapy groups in each of the urinary, bowel, and sexual domains exist. Among patients treated with orthotopic continent urinary diversion, functional impairments related to urinary incontinence and lack of urinary control account for the low observed urinary function scores. Cancer 2007. © 2007 American Cancer Society.